Unveiling the multi-target mechanisms of Zuo Gui Wan in Alzheimer's disease: An integrated study combining network pharmacology, Mendelian Randomization, and molecular docking

  • Brain Res Bull. 2026 Sep:243:111972. doi: 10.1016/j.brainresbull.2026.111972.
Ziyan Ma  1 ,  Zuli Yang  2 ,  Zhiqiang Xiao  2 ,  Bin Huang  3 ,  Xiaoping Wang  4
Affiliations
  • 1. School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China.
  • 2. Department of Neurology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
  • 3. Department of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
  • 4. Department of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China. Electronic address: [email protected].
PMID: 42259474 DOI: 10.1016/j.brainresbull.2026.111972
Abstract

Purpose: Zuo Gui Wan (ZGW), a traditional Chinese medicine formula, shows neuroprotective potential, but the mechanisms underlying its therapeutic effects on Alzheimer's disease (AD) remain unclear. This study aims to identify the active components, molecular targets, and biological pathways of ZGW in AD using an integrated systems pharmacology approach combining network analysis and causal inference.

Methods: Active ZGW ingredients and targets were sourced from TCMSP and BATMAN-TCM. Summary-data-based Mendelian Randomization (SMR) and colocalization analyses integrated eQTL and AD GWAS data to identify gene-AD associations. Network pharmacology, GO/KEGG enrichment, PPI analysis, and molecular docking were conducted. Selected targets were examined by CCK-8 assay and Western blot in an Aβ25-35-induced SH-SY5Y neuronal injury model treated with ZGW-containing rat serum.

Results: We identified 134 bioactive ZGW compounds targeting 391 AD-related genes. SMR prioritized six targets (ACE, Src, STAT1, LEP, EGFR, and MAPK3) associated with neuroinflammatory and cardiovascular pathways. Molecular docking suggested strong interactions between key compounds and targets, notably berberine with Src (-10.53 kcal/mol) and compound 1 (PubChem CID: 137704703) with MAPK3 (-17.22 kcal/mol). In the Aβ-induced neuronal model, ZGW-containing serum partially restored cell viability, reduced ERK1/2 and STAT1 phosphorylation, and increased ACE expression.

Conclusion: Integrated computational analyses prioritized six potential AD-related targets of ZGW, including ACE, Src, STAT1, LEP, EGFR, and MAPK3. Preliminary cellular experiments further supported the involvement of MAPK3/ERK and STAT1 signaling, with increased ACE expression observed after ZGW treatment. These findings provide mechanistic insight into the potential therapeutic effects of ZGW in AD.

Keywords
Alzheimer's Disease; Mendelian Randomization; Molecular Docking; Network Pharmacology; Zuo Gui Wan.
Products